CIBA SUBMITS Q-VEL DATA REANALYSIS TO SUPPORT MONOGRAPH STATUS
This article was originally published in The Tan Sheet
Executive Summary
CIBA SUBMITS Q-VEL DATA REANALYSIS TO SUPPORT MONOGRAPH STATUS of the quinine sulfate/vitamin E combination product for the treatment of nocturnal leg cramps in a Jan. 25 filing with FDA. Ciba Consumer maintained that the reanalysis "clearly [demonstrates] that, on the basis of the primary effectiveness endpoints studied, the quinine sulfate/vitamin E combination in Q- Vel was superior to quinine sulfate alone, and that quinine sulfate was superior to placebo for the prevention of nighttime leg cramps." The statistical reanalysis of a previously submitted study from Bio-Products, the developer of Q-Vel, was conducted by Ciba at the request of FDA.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning